Loading people...
Beth Seidenberg is the Founding Managing Director at Westlake Village BioPartners, an early-stage life sciences venture capital firm based in Westlake Village, California. Before launching her current firm in 2018, she spent over a decade as a General Partner at Kleiner Perkins and held senior research and development roles, including Chief Medical Officer and Head of Global Development at Amgen. Her pharmaceutical industry experience also includes executive positions at Bristol-Myers Squibb and Merck, where she helped introduce 10 products to the market. Since transitioning to venture capital in 2005, Seidenberg has incubated and invested in more than 40 biotechnology companies, achieving notable exits including the $5.1 billion acquisition of Tesaro by GlaxoSmithKline. The physician and investor currently focuses on deploying her firm's $450 million third fund to scale early-stage therapeutics startups addressing unmet clinical needs.
Beth Seidenberg stands as a prominent figure in the life sciences investment landscape, serving as a Managing Director at Westlake Village BioPartners. Her role at the firm involves not only identifying and funding promising new ventures but also actively participating in their creation and development. Westlake Village BioPartners is a venture capital firm dedicated to building and investing in innovative life science companies, and Dr. Seidenberg's deep operational and medical expertise is central to its mission.
Dr. Seidenberg's investment focus is primarily on early stage biotechnology and pharmaceutical companies that are developing novel therapeutics to address significant unmet medical needs. She is particularly adept at recognizing scientific breakthroughs with the potential to transform patient care, guiding these companies from concept through clinical development and beyond. Her strategic vision helps shape the future of medicine by backing ventures poised to deliver groundbreaking treatments.
Before co-founding Westlake Village BioPartners, Beth Seidenberg had a distinguished career that bridged both large pharmaceutical companies and venture capital. She was a highly influential Partner at Kleiner Perkins (KPCB), where she played a pivotal role in co-founding and investing in numerous successful biotech companies. Her tenure at KPCB solidified her reputation as a visionary investor capable of nurturing nascent ideas into industry leaders.
Prior to her venture capital career, Dr. Seidenberg held senior leadership positions in global pharmaceutical development. She served as Senior Vice President, Head of Global Development at Amgen, one of the world's leading biotechnology companies. Before Amgen, she was Senior Vice President, Head of Global Development and Chief Medical Officer at Tularik. Her extensive background also includes significant roles at Bristol-Myers Squibb and Merck Research Laboratories. This rich operational experience, combined with her medical doctor (MD) degree, provides her with an unparalleled understanding of the drug discovery and development process.
Among her notable contributions, Dr. Seidenberg has been instrumental in the founding and growth of several high-profile companies. These include Acelyrin, Neumora, Septerna, and T-knife Therapeutics, among others. Her ability to identify, build, and scale these enterprises underscores her profound impact on the biotechnology sector. Beth Seidenberg continues to drive innovation, leveraging her expertise to foster the next generation of life science breakthroughs.
Beth Seidenberg is a highly respected Managing Director at Westlake Village BioPartners, a venture capital firm specializing in life sciences. She is a physician, experienced drug developer, and a prolific investor known for founding and funding innovative biotechnology companies.
Beth Seidenberg primarily invests in early stage life science companies, focusing on novel therapeutics, drug discovery, and clinical development. Her portfolio includes biotechnology and pharmaceutical ventures aimed at addressing significant unmet medical needs.
Beth Seidenberg works as a Managing Director at Westlake Village BioPartners. This venture capital firm is dedicated to creating and investing in new life science companies, primarily in the biotechnology and pharmaceutical sectors.
